新的CAR T细胞疗法在治疗高级多细胞瘤方面显示出很高的功效和安全性。 New CAR T-cell therapies show high efficacy and safety in treating advanced multiple myeloma.

一个新的CAR T细胞疗法Arlo-cel显示,复发或复发性多骨髓瘤患者的复发率和可控制的安全性很高,总体回应率为94%,在第一阶段试验中完全回应率为71%。 A new CAR T-cell therapy, arlo-cel, demonstrated high response rates and manageable safety in patients with relapsed or refractory multiple myeloma, with a 94% overall response rate and 71% complete response rate in a phase 1 trial. 另一项研究发现,将针对GPRC5D和BDMA的两套CAR治疗疗法结合起来是安全和有效的,对严重预治疗的病人采取深入、持久的应对办法。 Another study found that combining two CAR T therapies targeting GPRC5D and BCMA was safe and effective, with deep, lasting responses in heavily pretreated patients. 第三种疗法,eque-cel, 达到96.3%的响应率和83.2%的完整响应率,最低的残余疾病负负率和耐久治疗率很高。 A third therapy, eque-cel, achieved a 96.3% response rate and 83.2% complete response rate, with high rates of minimal residual disease negativity and durable remissions. 所有三种疗法都显示出有利的安全特征,具有可管理的副作用,包括细胞释放综合症和神经毒性,但没有与治疗有关的死亡。 All three therapies showed favorable safety profiles, with manageable side effects including cytokine release syndrome and neurotoxicity, but no treatment-related deaths. 长期后续行动继续为所有人开展。 Long-term follow-up continues for all.